InfraScan, a medical device manufacturer based in Philadelphia, Pennsylvania, announced that the United States Food and Drug Administration approved its brain hematoma detector, the Infrascanner Model 2000.
According to a press release by the company, the Infrascanner Model 2000 was developed as as part of a joint initiative with the U.S. Marine Corps and the Navy. The device is a ruggedized version of the original Infrascanner, which received FDA two years ago. Both the original and ruggedized Infrascanner use specialized near-infrared scanning technology to detect hematomas (brain bleeding) through non-invasive techniques. Once patients have received a rapid diagnosis with the Infrascan system, patients can be sent for further confirmatory diagnostics.
Since hematomas can be caused by a variety of physical traumas, they are common in militarized areas. For example, hematomas can be caused by improvised explosive devices (IEDs). Since hematomas are a life-threatening emergency, a rapid diagnosis is essential for proper treatment of this medical condition.
Baruch Ben Dor is the CEO and president of InfraScan. In prepared remarks, he said, "FDA approval in the U.S. allows InfraScan to offer an industry first, powerful tool for use by civilian and military medical professionals to quickly triage head trauma patients." He continued, "Shortening the time to treatment through effective detection of intracranial bleeding can mean preserving brain function in a patient and even saving lives."